Case Western Reserve University

Abbott Laboratories Corporation

University of Pittsburgh

The Cleveland Clinic Foundation

Robert H Miller

Paul J Tesar

Fadi J Najm

Madhup K Dhaon

Ronald T Stanko

Kent Lee Cipollo

Mark Anthony McCamish

Edwin O Lundell

Nickki L Parlet

John A Houbion

Bruce Trapp

Stephen M Selkirk

John William McEwen

Mary F Henningfield

A method of promoting remyelination in a subject in need thereof includes administering to the subject a therapeutically effective amount of at least one (1,3) Diazole compound, wherein the therapeutically effective amount is the amount effective to induce endogenous oligodendrocyte precursor cell (OPC) differentiation in the subject's central nervous system.

Method of promoting remyelination

The present invention relates to the reprogramming of differentiated somatic cells, such as those differentiated cells that arise from embryonic mesoderm, into glial cells. Glial cells produced from this reprogramming are functionally equivalent to glial cells that arise from ectodermal origins.

Cell fate conversion of differentiated somatic cells into glial cells

The present invention provides methods for generating oligodendrocyte progenitor cells from pluripotent cells, as well as methods for sustaining these oligodendrocyte progenitor cells in relatively pure cultures for long periods of time. The present invention also provides methods for further differentiating these oligodendrocyte progenitor cells into various glial cells.

Differntiation method for production of glial cell population

Glial cells and oligodendrocytes produced by reprogramming somatic cells with Sox10, Olig2 and Nkx6.2

Differentiation method for production of glial cell populations

The present invention provides compositions and methods for studying neuropathy. The compositions and methods provided herein are particularly useful for screening agents of therapeutic and/or diagnostic potential.

Targeted cell death

An isolated multipotent neural stem cells has a phenotype identified by expression of the protein &#x3b2;-tubulin IV and Olig2 and the absence of the proteins NG2, PLP, and GFAP.

Multipotent neural stem cells

Treating mammals having ischemic bowel with a therapeutic quantity of pyruvate enterally or parenterally will retard neutrophil infiltration and retain morphology during and following the bowel ischemia. The pyruvate is introduced into the patient enterally or parenterally during the bowel ischemia or the succeeding bowel reperfusion and, preferably, prior to the bowel ischemia. The pyruvate dosage is from 1% to 20% by weight of the patient's caloric intake.

Retarding neutrophil infiltration ad morphologic reduction in ischemic

A therapeutic method is provided to reduce ischemia/reperfusion injury to the heart muscle by perfusing pyruvylglycine into the circulatory system of a patient who has had a heart attack or suffered coronary occlusion.

Use of pyruvylglycine to treat ischemia/reperfusion injury following

A method for administering pyruvate is disclosed which comprises administering a therapeutically effective amount of a pyruvate precursor to a mammal in the form of pyruvamide or a pyruvyl-amino acid. The pyruvyl-amino acid is preferably selected from the group comprising pyruvyl-glycine, pyruvyl-alanine, pyruvyl-leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvyl-phenylalanine, pyruvyl-proline and pyruvyl-sarcosine, and their amides and esters as well as their salts. Associated with the administration of a pyruvate precursor to a mammal in accordance with this invention are improved insulin resistance, lower fasting insulin levels, and reduced fat gain. Novel methods of synthesizing several pyruvate precursors are also disclosed.

Parental administration of pyruyate precursors

A method for administering pyruvate is disclosed which comprises administering a therapeutically effective amount of a pyruvate precursor to a mammal in the form of pyruvamide or a pyruvyl-amino acid. The pyruvyl-amino acid is preferably selected from the group comprising pyruvyl-glycine, pyruvyl-alanine, pyruvyl-leucine, pyruvyl-valine, pyruvyl-isoleucine, pyruvylphenyl al anine, pyruvyl-proline and pyruvyl-sarcosine, and their amides and esters as well as their salts. Associated with the administration of a pyruvate precursor to a mammal in accordance with this invention are improved insulin resistance, lower fasting insulin levels, and reduced fat gain. Novel methods of synthesizing several pyruvate precursors are also disclosed.

Growing community of inventors

Cleveland Heights, OH, United States of America

Robert H Miller